Wielding its new power to enforce postmarket study requirements, FDA sent Merck & Co. Inc. a warning letter for missing a deadline to complete a postmarketing study of Januvia (sitagliptin) and Janumet (sitagliptin/metformin) by more than 20 months.
In a Feb. 17 letter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?